Advertisement
Advertisement
U.S. markets open in 7 hours 49 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.6500+0.1900 (+5.49%)
At close: 04:00PM EDT
3.6500 0.00 (0.00%)
After hours: 07:34PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close3.4600
Open3.7000
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range3.5450 - 3.7000
52 Week Range2.3000 - 15.5000
Volume239,621
Avg. Volume140,829
Market Cap166.041M
Beta (5Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-2.9520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CLLS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cellectis S.A.
    Analyst Report: Intellia Therapeutics, Inc.Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
Advertisement
Advertisement